Menu

Top Stories

Published on Thursday, May 28, 2015

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial in The Lancet, one of the world’s oldest and most prestigious medical journals.

The Lancet article was posted online this week.

When the results were first announced at the international conference of the American Thoracic Society (ATS) in 2013, lead author Kenneth Chapman, MD, director of the Asthma and Airway Centre of the University Health Network in Toronto, Canada, called the trial “the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 Antitrypsin Deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease.”

The Alpha-1 Foundation hailed the trial results and The Lancet publication. "We congratulate CSL on this landmark clinical trial, which provides the strongest evidence yet that augmentation therapy preserves the lung tissue of individuals with Alpha-1-related lung disease," said John Walsh, Foundation president and CEO. "We hope these results will support Alpha-1 communities around the world in their efforts to win access to therapy.”

Walsh said, “The Foundation has communicated its support for acceptance of the RAPID data as proof of efficacy of augmentation therapy to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (the European equivalent of the FDA), and has continued a dialogue with both agencies to urge acceptance of these findings.”

CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period, followed by a two year of open-label extension study in which all subjects were offered augmentation therapy. “We applaud CSL for its commitment of time and effort to conduct this multinational, multi-year study, and we’re delighted that The Lancet has published the RAPID Trial results,” said Walsh. 

The Lancet article says that an interim analysis of data from the two-year extension trial suggest that early treatment with augmentation therapy shows persistent efficacy in patients with Alpha-1 and emphysema. In addition, when patients who had been receiving a placebo in the original two-year trial switched to treatment with augmentation therapy, their lung density decline (which was more rapid than the treated group in the main study) slowed to the same rate as the treatment group. “These findings should encourage early introduction of augmentation therapy [in patients with emphysema due to Alpha-1] and should stimulate further research into optimum dosing,” says the Lancet article.

Robert Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet, was a co-author of the Lancet article.

The RAPID Trial is the first well-powered randomized, placebo-controlled trial to use CT scan lung density as the primary outcome measure. CT scans are currently considered the most sensitive measure of emphysema detection. The trial was conducted at 28 sites in the United States, Europe, Canada, Australia and Russia.

The multi-center, multi-national trial randomized patients with homozygous Alpha-1 (ZZ) to receive either alpha-1 antitrypsin augmentation therapy intravenously at 60 mg/kg weekly or a placebo over two years. CT scan lung density was measured at baseline, three months, one and two years. Secondary endpoints included spirometry, changes in exercise capacity and the rate of pulmonary exacerbations over two years.

The annual rate of lung density loss was significantly less in augmentation-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one-sided). Secondary outcome variables and adverse events were not significantly different between groups, according to the article. There was one death in the augmentation therapy group and three in the placebo group.

Attached is the full article published in The Lancet, with an accompanying editorial by Ronald Crystal, MD, Department of Genetic Medicine, Weill Cornell Medical College.

Photo at top: Ken Chapman, MD. Below: John Walsh, left, and Robert Sandhaus, MD.


Print

Alpha-1 Foundation expresses gratitude to plasma donors

Wednesday, February 13, 2019
Recently, the New York Times published an article that, in the opinion of the Alpha-1 Foundation, portrayed an image of plasma donors that only focused on one side of the story.  Plasma donors can come from all backgrounds and levels of...
Divider

NORD continues to bridge the gap between patients and their health care

Thursday, February 7, 2019
Since its inception in the early 1980s, the National Organization for Rare Disorders (NORD) has been instrumental in providing assistance to individuals affected by rare diseases and their families; it was influential in the Orphan Drug Act of...
Divider

Alpha-1 Foundation welcomes new President and CEO

Monday, February 4, 2019
The Alpha-1 Foundation Board of Directors is excited to announce the appointment of Miriam O’Day as the new president and chief executive officer (CEO) of the Alpha-1 Foundation. “We thank Miriam for serving as interim CEO, since...
Divider

Tips and resources for Alphas and the cold weather

Wednesday, January 30, 2019
Cold weather conditions can worsen symptoms for lung affected Alphas and for patients with Chronic Obstructive Pulmonary Disease (COPD), as low temperatures can often lead to fatigue and windy days can cause shortness of breath. Also, the dry...
Divider

Alpha friend and leader Jim Quill passes away

Monday, January 14, 2019
It is with a heavy heart that the Alpha-1 Foundation shares the passing of a dear friend and leader, James Quill on Sunday, January 13th, 2019 in Bluffton, South Carolina. He was 67. Jim was on the Alpha-1 Foundation Board of Directors since...
Divider

Shire is now part of Takeda

Tuesday, January 8, 2019
Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in...
Divider

Apic Bio announces $40M financing to advance novel gene therapies for rare genetic disorders

Monday, January 7, 2019
Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, announced the completion of a $40 million Series A financing led by Morningside Venture Investments, Ltd. Existing...
Divider

FDA sends warnings after several people hospitalized with infections from stem cell shots

Friday, December 21, 2018
Twelve patients became seriously ill after receiving injections that supposedly contained stem cells from umbilical cord blood, according to the U.S. Food and Drug Administration (FDA), which issued a warning to the California company, Genetech,...
Divider

Near and far, the 2018 Virtual Walk raised the bar

Tuesday, December 18, 2018
Alphas from all over the United States joined together in November for the annual Alpha-1 Foundation Virtual Walk. For 30 days, in 36 states, friends and family supported one strong mission to find a cure. From near and far, 68 teams and 40 solo...
Divider

Giants in chest medicine: Gerard M. Turino, MD

Thursday, December 13, 2018
“My initial encounter with Gerry Turino took place in 1976, during my first year as a pathology intern at Columbia-Presbyterian Hospital. I was referred to him by a colleague, after mentioning my interest in connective tissue research. When...
Divider

Medicare Open Enrollment for 2019 coverage

Thursday, December 6, 2018
Medicare health and drug plan holders can make changes annually on costs, coverage, and which providers and pharmacies are in their networks. From October 15th, 2018, through December 7th, 2018, people with Medicare can change their health plan...
Divider

Zemaira update

Tuesday, December 4, 2018
The Alpha-1 Foundation was informed by CSL Behring that Zemaira, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1), returned to normal distribution on Monday, December 3rd, 2018. This is...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive